News

As per the agreement, ThromboGenics will receive an upfront payment of €75m and also a further €90m in potential near-term milestone payments. Additional milestones bring the potential total

The company plans to launch CAMBIA (diclofenac potassium for oral solution) in Canada in the second half of 2012. The water-soluble, buffered diclofenac potassium powder was developed leveraging

Sanofi will commercialize Pluromed’s LeGoo, a gel indicated for temporary endovascular occlusion of blood vessels during surgical procedures. LeGoo is a FDA approved and CE marked product. This

The 104,000ft² expansion majorly includes laboratory space for research and development around antibiotics and other acute care products and a molecular modeling room. Built to the LEED Silver

The research institute will supply XTL with clinical data and analyses as part of the agreement. The data and analyses would be based on the Institute’s database in

The investment will expand the production of active raw materials to over 3,000ltrs. The expanded facility is dedicated to the production of small molecules and proteins which require

Under the agreement, ThromboGenics will receive an upfront payment of €75m, is also entitled to a further €90m in potential near-term milestone payments. In addition, ThromboGenics will receive

JPM-TMT joint project manager David Hough said the drug showed that it can mitigate flu symptoms by interfering with the influenza replication process. In earlier animal studies and

The suit is based on an ANDA filed by Sandoz seeling approval to market a generic version of the 10mg/mL strength of Remodulin. Sandoz’s ANDA alleges that the